Choi Kyunghak, Han Youngjin, Ko Gi-Young, Cho Yong-Pil, Kwon Tae-Won
Department of Surgery, University of Ulsan College of Medicine and Asan Medical Center, Songpa-Gu, Seoul, Republic of Korea.
Department of Radiology, University of Ulsan College of Medicine and Asan Medical Center, Songpa-Gu, Seoul, Republic of Korea.
Ann Vasc Surg. 2018 Aug;51:187-191. doi: 10.1016/j.avsg.2018.02.042. Epub 2018 Jun 9.
The objective of the study was to compare the treatment outcomes and cost of endovascular aortic aneurysm repair (EVAR) and open surgical repair (OSR) in patients with an abdominal aortic aneurysm (AAA) at a single center.
Patients treated for an AAA at a single center between January 2007 and December 2012 were retrospectively identified and classified based on the treatment they received (EVAR or OSR). Patient demographics and in-hospital costs were recorded. Long-term survival was calculated using the Kaplan-Meier method.
During the study period, 401 patients with AAA were treated at Asan Medical Center. Among these cases, 226 were treated with EVAR (56%) and 175 received OSR (44%). The mean age of the EVAR group was higher than that of the OSR group (71.25 ± 7.026 vs. 61.26 ± 8.175, P < 0.001). The need for intraoperative transfusion and total length of in-hospital stay were significantly lower in the EVAR group (P < 0.001). The OSR group showed significantly reduced rates of overall mortality (P = 0.003), overall reintervention (P = 0.001), and long-term survival (63.98 ± 1.86 vs. 99.54 ± 3.17, P < 0.001). The OSR group was charged significantly less than the EVAR group ($12,879.21 USD vs. $18,057.78 USD, P < 0.001).
EVAR has advantages over OSR in terms of short-term mortality, in-hospital length of stay, and rates of perioperative transfusion. However, OSR is associated with better long-term survival, lower reintervention rates, and lower costs.
本研究的目的是比较单中心腹主动脉瘤(AAA)患者接受血管腔内主动脉瘤修复术(EVAR)和开放手术修复术(OSR)的治疗效果及费用。
回顾性纳入2007年1月至2012年12月在单中心接受AAA治疗的患者,并根据其接受的治疗方式(EVAR或OSR)进行分类。记录患者人口统计学资料和住院费用。采用Kaplan-Meier法计算长期生存率。
研究期间,峨山医学中心共治疗401例AAA患者。其中,226例接受EVAR治疗(56%),175例接受OSR治疗(44%)。EVAR组的平均年龄高于OSR组(71.25±7.026岁 vs. 61.26±8.175岁,P<0.001)。EVAR组术中输血需求和住院总时长显著更低(P<0.001)。OSR组的总死亡率(P=0.003)、总再次干预率(P=0.001)显著降低,长期生存率更高(63.98±1.86 vs. 99.54±3.17,P<0.001)。OSR组的收费显著低于EVAR组(12,879.21美元 vs. 18,057.78美元,P<0.001)。
在短期死亡率、住院时长和围手术期输血率方面,EVAR优于OSR。然而,OSR与更好的长期生存率、更低的再次干预率和更低的费用相关。